
Iterative Health is a leading healthcare technology and services company dedicated to addressing challenges in gastrointestinal care. They empower healthcare professionals, researchers, and life sciences organizations with innovative solutions, focusing on AI-powered technology and services. Their products, including Clinical Trial Optimization and SKOUT, aim to optimize clinical trials and enhance patient care, ultimately improving outcomes for patients worldwide. With a commitment to innovation, Iterative Health is transforming how clinical trials are conducted, making them faster and more accessible.

Iterative Health is a leading healthcare technology and services company dedicated to addressing challenges in gastrointestinal care. They empower healthcare professionals, researchers, and life sciences organizations with innovative solutions, focusing on AI-powered technology and services. Their products, including Clinical Trial Optimization and SKOUT, aim to optimize clinical trials and enhance patient care, ultimately improving outcomes for patients worldwide. With a commitment to innovation, Iterative Health is transforming how clinical trials are conducted, making them faster and more accessible.
Founded: 2017
Headquarters: Cambridge, Massachusetts
Focus: Clinical AI / computer vision for colorectal cancer and IBD
Recent stage: Series B (announced Jan 19, 2022)
Total funding (reported): Approximately $193.7M
Gastrointestinal disease diagnosis and clinical trial optimization (colorectal cancer and inflammatory bowel disease).
2017
Biotechnology
Series B announced Jan 19, 2022; investor syndicate includes strategic and VC participants
“Backed by a syndicate including Insight Partners, Clearlake Capital Group, Johnson & Johnson Innovation, Eli Lilly, Obvious Ventures, Breyer Capital, and Alumni Ventures”